Oric provides initial Phase 1b data for ORIC-944, 2024 milestones

ORIC Pharmaceuticals announced initial data for its PRC2 inhibitor ORIC-944, operational highlights for 2023, and anticipated upcoming milestones. Initial Phase 1b Data for ORIC-944: As of December 10, 2023, the initial Phase 1b monotherapy data for ORIC-944, a potent and selective allosteric inhibitor of PRC2, in patients with metastatic prostate cancer demonstrated: Potential best-in-class drug properties, including clinical half-life consistent with preclinical prediction of greater than10 hours, which is superior to other PRC2 inhibitors and supports QD dosing; No signs of CYP autoinduction that is seen with first-generation PRC2 inhibitors; Robust target engagement with maximal decrease in H3K27me3 in monocytes from peripheral blood samples at doses as low as 200 mg QD, with low inter-patient variability; and Favorable safety with only grade 1 and 2 treatment-related adverse events at dose levels corresponding with strong target engagement. Emerging profile with superior drug properties support advancement into combination development in prostate cancer with AR inhibitor(s). 2023 Key Accomplishments: ORIC-114: a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor: Presented initial data from the ongoing Phase 1b dose escalation trial. Presented preclinical data for ORIC-114 at ESMO Congress 2023. ORIC-944: a potent and selective allosteric inhibitor of PRC2: Presented preclinical data highlighting a comprehensive biomarker strategy for the ongoing Phase 1b trial in metastatic prostate cancer. Demonstrated via preclinical studies the potential for ORIC-944 to synergize with enzalutamide and other AR inhibitors in prostate cancer. ORIC-533: a highly potent, orally bioavailable small molecule inhibitor of CD73: Presented initial data from Phase 1b trial of ORIC-533 in patients with relapsed/refractory multiple myeloma at the 2023 ASH Annual Meeting. Expect to complete dose escalation for the Phase 1b trial of ORIC-533 in the first quarter of 2024, and company plans to pursue strategic partnership for combination studies. Discovery Pipeline: Presented preclinical data confirming the therapeutic potential of highly selective PLK4 inhibitors as a synthetic lethal therapy for TRIM37 amplified breast cancers at the 2023 AACR Annual Meeting. Advanced ORIC-613, a novel, highly selective PLK4 inhibitor, through IND enabling studies. Anticipated Program Milestones: ORIC-944 initiation of combination study with AR inhibitor: 1H 2024; ORIC-944 program update: mid-2024; ORIC-114 initiation of dose expansion in multiple cohorts: 1H 2024; ORIC-114 updated Phase 1b data: 1H 2025.